Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Drug Resistance

Free Subscription Articles published in Int J Antimicrob Agents Retrieve available abstracts of 200 articles: HTML format

Single Articles

October 2025
1. LIU Y, Thong S, Moreira W, Yeo JH, et al
   Clinical application of customized and non-customized bacteriophage therapy in patients with refractory/resistant bacterial infections: A systematic review and meta-analysis.
   Int J Antimicrob Agents. 2025;66:107570.
   PubMed     Abstract available
   
   
   
2. TULLAYAPRAYOUCH K, Phuadraksa T, Luk-In S, Pornsuwan S, et al
   Development of multiplex recombinase polymerase amplification for the rapid detection of five carbapenemase (bla(KPC), bla(NDM), bla(OXA-48)-like, bla(IMP), and bla(VIM)) and 10 mcr (mcr-1 to mcr-10) genes in blood cultures.
   Int J Antimicrob Agents. 2025;66:107567.
   PubMed     Abstract available
   
   
   
3. CHOWDHURY FR, Banari V, Lesnic V, Zhanel GG, et al
   Large scale laboratory evolution uncovers clinically relevant collateral antibiotic sensitivity.
   Int J Antimicrob Agents. 2025;66:107564.
   PubMed     Abstract available
   
   
   
4. SASTRE-FEMENIA MA, Fernandez-Munoz A, Gomis-Font MA, Taltavull B, et al
   Spanish nationwide survey of Pseudomonas aeruginosa cefiderocol susceptibility and resistance mechanisms.
   Int J Antimicrob Agents. 2025;66:107563.
   PubMed     Abstract available
   
   
   
5. TANG B, Meng T, Tian L, Zhong M, et al
   Within-host resistance evolution of ST15 Klebsiella pneumoniae in an ICU immunosuppressed patient under antibiotic pressure of polymyxins, ceftazidime-avibactam, and meropenem.
   Int J Antimicrob Agents. 2025;66:107554.
   PubMed     Abstract available
   
   
   
6. KUAI J, Zhao Y, Wang R, Zhang Y, et al
   Elucidating adaptive compensatory tigecycline resistance mechanisms of RamA, RarA and SoxS in Klebsiella pneumoniae.
   Int J Antimicrob Agents. 2025;66:107551.
   PubMed     Abstract available
   
   
   September 2025
7. HAN R, Tang C, Yu F, Li T, et al
   Extraintestinal pathogenic Escherichia coli (ExPEC) O-serotype distribution and antibiotic resistance profiles among the aging population in China: A longitudinal, multi-center study.
   Int J Antimicrob Agents. 2025 Sep 2:107607.
   PubMed     Abstract available
   
   
   
8. LEE YL, Tan MC, Chen PJ, Shiau YR, et al
   In vitro activity of cefepime-zidebactam, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and other comparators against imipenem-non-susceptible Pseudomonas aeruginosa in Taiwan, 2022.
   Int J Antimicrob Agents. 2025;66:107550.
   PubMed     Abstract available
   
   
   
9. ABRIL D, Solorzano P, Leal AL, Forero-Hurtado D, et al
   Ceftazidime/avibactam resistance in Enterobacter cloacae due to the acquisition of a small pHAD28-like plasmid harbouring bla(KPC-33).
   Int J Antimicrob Agents. 2025;66:107540.
   PubMed     Abstract available
   
   
   
10. LYNCH K, Martson AG
    The importance of drug exposure in the development of cytomegalovirus resistance.
    Int J Antimicrob Agents. 2025;66:107537.
    PubMed     Abstract available
    
    
    
11. CERCENADO E, Alcala L, Irigoyen-von-Sierakowski A, Rodriguez-Sanchez B, et al
    Activity of imipenem-relebactam, ceftolozane-tazobactam and comparators against clinical isolates of Enterobacterales and Pseudomonas aeruginosa causing severe infections in hematological and oncological patients: A prospective multicenter study.
    Int J Antimicrob Agents. 2025;66:107534.
    PubMed     Abstract available
    
    
    
12. ZHANG XW, Huang XY, Zhou ZY, Li BL, et al
    Genetic framework and evolutionary dynamics of mcr-positive Klebsiella pneumoniae from 2000 to 2023.
    Int J Antimicrob Agents. 2025;66:107533.
    PubMed     Abstract available
    
    
    
13. TERRILL AE, Tait JR, Rogers KE, Lee WL, et al
    Effects of different resistance mechanisms on bacterial response to meropenem, ciprofloxacin, and their combination described by next-generation mechanism-based modelling.
    Int J Antimicrob Agents. 2025;66:107528.
    PubMed     Abstract available
    
    
    August 2025
14. GAO S, Quan Y, Song S, Jin W, et al
    Disrupting bacterial metabolism by targeting LDH reverses Streptococcus suis aminoglycoside resistance.
    Int J Antimicrob Agents. 2025 Aug 20:107599.
    PubMed     Abstract available
    
    
    
15. AMARLAPUDI MR, Balasubramaniam C, Akash, Singh H, et al
    Microbiome and Antibiotic Resistance Profile of Milk and Faeces from Cattle in an Organized Dairy Production System.
    Int J Antimicrob Agents. 2025 Aug 13:107590.
    PubMed     Abstract available
    
    
    
16. FENG X, Li S, Huang D, Tan N, et al
    Emergence of carbapenem-resistant XDR Salmonella enterica in pediatric patients in South China: a genomic perspective study.
    Int J Antimicrob Agents. 2025 Aug 6:107589.
    PubMed     Abstract available
    
    
    
17. ZHANG Y, Li Z, Shi H, Lei Z, et al
    High-level ceftazidime-avibactam resistance by in-host evolution of bla(KPC) genes: Emergence of a novel bla(KPC-102) variant and increase of bla(KPC-33) copy number in Klebsiella pneumoniae strains from a lung transplantation recipient.
    Int J Antimicrob Agents. 2025;66:107521.
    PubMed     Abstract available
    
    
    
18. YANG J, Yue H, Wang W, Lin C, et al
    Synergistic activity of menadione in combination with colistin against colistin-susceptible and colistin-resistant Gram-negative bacteria.
    Int J Antimicrob Agents. 2025;66:107523.
    PubMed     Abstract available
    
    
    
19. WEI W, Lian Y, Peng Y, Kan B, et al
    Drug resistance phenotypes of clinical Klebsiella pneumoniae isolates in the past 20 years in China: A systematic review and meta-analysis.
    Int J Antimicrob Agents. 2025;66:107520.
    PubMed     Abstract available
    
    
    
20. H ALBEHAIJANI S, Huynh T, Boyce KJ
    Cellular and genetic changes during and after fluconazole exposure in Cryptococcus neoformans.
    Int J Antimicrob Agents. 2025;66:107519.
    PubMed     Abstract available
    
    
    
21. MALIK MA, Manzoor S, Ashraf J
    Bayesian evaluation of phage therapy efficacy against multidrug-resistant Acinetobacter baumannii.
    Int J Antimicrob Agents. 2025;66:107508.
    PubMed     Abstract available
    
    
    July 2025
22. LIN HH, Lin YT, Chen CH, Tseng KH, et al
    Prediction of methicillin-resistant Staphylococcus aureus and carbapenem-resistant Klebsiella pneumoniae from Raman spectra by Artificial Intelligent Raman Detection and Identification System (AIRDIS) with machine learning.
    Int J Antimicrob Agents. 2025 Jul 30:107587.
    PubMed     Abstract available
    
    
    
23. ELIAS R, Phelan JE, Lito L, Caneiras C, et al
    Genome-Wide Analysis and Longitudinal Study of Klebsiella pneumoniae in Portugal: Tracing the Evolution and Spread of Carbapenem Resistance.
    Int J Antimicrob Agents. 2025 Jul 30:107583.
    PubMed     Abstract available
    
    
    
24. YAO ZC, Sun Y, Ma ZX, Chen HC, et al
    Longitudinal Analysis of Carbapenem-Resistant Escherichia coli in a Southern Chinese Hospital (2015-2021): Epidemiology, Genetics, and Resistance Mechanisms.
    Int J Antimicrob Agents. 2025 Jul 19:107577.
    PubMed     Abstract available
    
    
    
25. WOH PY, Soengkono F, Chen Y, Hasan ZHA, et al
    Genomic insights into nontyphoidal Salmonella: Prediction of antimicrobial resistance with whole genome-based machine learning.
    Int J Antimicrob Agents. 2025 Jul 15:107575.
    PubMed     Abstract available
    
    
    
26. CHEN Y, Hong Y, Wang X, Cheng X, et al
    Profiling of omadacycline resistance in clinical MRSA: A nationwide genomic survey and in vitro evolutionary analysis.
    Int J Antimicrob Agents. 2025;66:107499.
    PubMed     Abstract available
    
    
    
27. JEAN SS, Lai CC, Ho SJ, Liu IM, et al
    Geographic variations in distributions of carbapenemase-encoding genes, susceptibilities, and minimum inhibitory concentrations of inpatient meropenem-resistant Enterobacterales to ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam-avibactam
    Int J Antimicrob Agents. 2025;66:107500.
    PubMed     Abstract available
    
    
    
28. WU Z, Famous M, Stoikidou T, Bowden FES, et al
    Unravelling AMR dynamics in the rumenofaecobiome: Insights, challenges and implications for One Health.
    Int J Antimicrob Agents. 2025;66:107494.
    PubMed     Abstract available
    
    
    June 2025
29. FAXEN L, Muller V, Chatzopoulou M, Lindsjo OK, et al
    Antibiotic susceptibility to new antibiotics and genetic characterisation of carbapenemase-producing Enterobacterales: low activity of cefiderocol against NDM-producing isolates.
    Int J Antimicrob Agents. 2025 Jun 17:107553.
    PubMed     Abstract available
    
    
    
30. VECILLA DF, Gutierrez MJU, Toboso MCN, Inchaurza KZ, et al
    Genetic characterization of extensively drug-resistant bla(CTX-M-27)Shigella sonnei clusters among men who have sex with men in a region of northern Spain.
    Int J Antimicrob Agents. 2025;65:107490.
    PubMed     Abstract available
    
    
    
31. TAIT JR, Agyeman AA, Lopez-Causape C, Deveson-Lucas D, et al
    Multiomics informed mathematical model for meropenem and tobramycin against hypermutable Pseudomonas aeruginosa.
    Int J Antimicrob Agents. 2025;65:107488.
    PubMed     Abstract available
    
    
    May 2025
32. TAIE A, Gheorghe M, Amos J, Morton A, et al
    Antimicrobial Resistance Trends, Predictors, and Burden in England: A retrospective study using the Clinical Practice Research Datalink from 2015-2021.
    Int J Antimicrob Agents. 2025 May 13:107535.
    PubMed     Abstract available
    
    
    
33. HAN X, Song M, Yu Q, Zhou J, et al
    Unveiling the Clonal Dynamics and transmission mechanism of Carbapenem-Resistant Klebsiella pneumoniae in the ICU environment.
    Int J Antimicrob Agents. 2025 May 6:107532.
    PubMed     Abstract available
    
    
    
34. MONTERO MM, Domene-Ochoa S, Prim N, Lopez-Causape C, et al
    Pharmacodynamic interaction of apotransferrin and anti-pseudomonal antibiotics against extensively drug-resistant Pseudomonas aeruginosa in a dynamic PK/PD model.
    Int J Antimicrob Agents. 2025;65:107477.
    PubMed     Abstract available
    
    
    
35. GAO S, Liu B, Yuan S, Quan Y, et al
    Cross-talk between signal transduction systems and metabolic networks in antibiotic resistance and tolerance.
    Int J Antimicrob Agents. 2025;65:107479.
    PubMed     Abstract available
    
    
    April 2025
36. BOYS MTH, Pletzer D
    A review of recently discovered mechanisms of cephalosporin resistance in Pseudomonas aeruginosa.
    Int J Antimicrob Agents. 2025 Apr 28:107527.
    PubMed     Abstract available
    
    
    
37. ETIENNE F, Lurier T, Yugueros-Marcos J, Mateus ALP, et al
    Is use of antimicrobial growth promoters linked to antimicrobial resistance in food-producing animals? A systematic review.
    Int J Antimicrob Agents. 2025 Apr 4:107505.
    PubMed     Abstract available
    
    
    
38. ALLAW F, Vu Thi Lan H, Nagao M, Ndegwa L, et al
    Antibiotic shortages: An overview by the alliance for the prudent use of antibiotics (APUA).
    Int J Antimicrob Agents. 2025;65:107456.
    PubMed     Abstract available
    
    
    
39. YANG Z, Lim TP, Mohamed Yusoff NB, Wong CSL, et al
    In vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates collected from two general hospitals in Singapore.
    Int J Antimicrob Agents. 2025;65:107447.
    PubMed     Abstract available
    
    
    March 2025
40. LIAO W, Quan J, Huang L, Zhou M, et al
    Emergence of a Clinical Carbapenem Resistant Escherichia coli Co-Harboring bla(NDM-5) and mcr-1.1 on the Same Plasmid.
    Int J Antimicrob Agents. 2025 Mar 24:107495.
    PubMed     Abstract available
    
    
    
41. AITHAL S, Toh G, Guo H, Hildon ZJ, et al
    Comparing the Knowledge, Attitudes, and Practices of Antibiotic Use and Antimicrobial Resistance for Cats and/or Dogs amongst Pet Owners in Singapore: A Cross-sectional Study.
    Int J Antimicrob Agents. 2025 Mar 9:107489.
    PubMed     Abstract available
    
    
    
42. CHEN X, Sun Z, Chen J, Xu X, et al
    The hidden threat: Klebsiella pneumoniae may develop co-resistance to colistin and cefiderocol under pressure of colistin.
    Int J Antimicrob Agents. 2025;65:107445.
    PubMed     Abstract available
    
    
    
43. TAVARES RDS, Tacao M, Henriques I
    Integrons are key players in the spread of beta-lactamase-encoding genes.
    Int J Antimicrob Agents. 2025;65:107421.
    PubMed     Abstract available
    
    
    
44. ZHOU P, Gao H, Li M, Wu C, et al
    Characterization of a novel KPC-2 variant, KPC-228, conferring resistance to ceftazidime-avibactam in an ST11-KL64 hypervirulent Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2025;65:107411.
    PubMed     Abstract available
    
    
    February 2025
45. CHENG Y, Zhou L, Wang D, Li X, et al
    Inhaled Alone versus Inhaled Plus Intravenous Polymyxin B for the Treatment of Pneumonia Due to Carbapenem-Resistant Gram-Negative Bacteria: A Prospective Randomized Controlled Trial.
    Int J Antimicrob Agents. 2025 Feb 27:107483.
    PubMed     Abstract available
    
    
    
46. DONG X, Xiang Y, Shen P, Xiao Y, et al
    Clinical emergence of Providencia zhejiangensis sp. nov. and Providencia xihuensis sp. nov.: Genomic insights into antimicrobial resistance and geographical distribution.
    Int J Antimicrob Agents. 2025;65:107484.
    PubMed     Abstract available
    
    
    
47. CHEN M, Jiang S, Sun L, Wang H, et al
    "Seesaw effect" between daptomycin and ceftobiprole in daptomycin-resistant methicillin-resistant staphylococcus aureus isolates.
    Int J Antimicrob Agents. 2025 Feb 20:107469.
    PubMed     Abstract available
    
    
    
48. SODAGARI HR, Sohail MN, Varga C
    Temporal, regional, and demographic differences among antimicrobial-resistant domestic Campylobacter jejuni human infections across the United States, 2013-2019.
    Int J Antimicrob Agents. 2025 Feb 20:107467.
    PubMed     Abstract available
    
    
    
49. LI Y, Liu X, Yao H, Zhao X, et al
    The evolution of carbapenem-resistant Pseudomonas aeruginosa in the COVID-19 era: a global perspective and regional insights.
    Int J Antimicrob Agents. 2025 Feb 17:107466.
    PubMed     Abstract available
    
    
    
50. JU X, Xiong P, Yan Z, Chen G, et al
    Emergence of carbapenem-resistant Citrobacter spp. across human, animal, and water environments in China.
    Int J Antimicrob Agents. 2025 Feb 12:107463.
    PubMed     Abstract available
    
    
    
51. FAROOQ S, Talat A, Dhariwal A, Petersen FC, et al
    Transgenerational Gut Dysbiosis: Unveiling the Dynamics of Antibiotic Resistance through Mobile Genetic Elements from Mothers to Infants.
    Int J Antimicrob Agents. 2025 Feb 5:107458.
    PubMed     Abstract available
    
    
    
52. XIAO Y, Xu Y, Han W, Wang B, et al
    Sub-minimum inhibitory concentrations of Rifampicin Attenuate Methicillin-resistant Staphylococcus aureus Virulence by Suppressing SaeRS Two-Component System and Arginine metabolism-related pathways.
    Int J Antimicrob Agents. 2025 Feb 3:107459.
    PubMed     Abstract available
    
    
    
53. ZHANG J, Ju Y, Li L, Hameed HMA, et al
    MtrAB two-component system is crucial for the intrinsic resistance and virulence of Mycobacterium abscessus.
    Int J Antimicrob Agents. 2025;65:107442.
    PubMed     Abstract available
    
    
    
54. TEICHMANN L, Pasman R, Luitwieler S, Varriale C, et al
    Adaptation of Escherichia coli to ciprofloxacin and enrofloxacin: Differential proteomics of the SOS response and RecA-independent mechanisms.
    Int J Antimicrob Agents. 2025;65:107420.
    PubMed     Abstract available
    
    
    
55. RAAIJMAKERS J, Ruth MM, Schildkraut JA, Hombergh EVD, et al
    Replacing rifampicin with minocycline increases the activity of the treatment regimen for Mycobacterium avium complex pulmonary disease in a dynamic hollow-fibre system.
    Int J Antimicrob Agents. 2025;65:107423.
    PubMed     Abstract available
    
    
    
56. XIANG X, Kong J, Zhang J, Zhang X, et al
    Multiple mechanisms mediate aztreonam-avibactam resistance in Klebsiella pneumoniae: Driven by KPC-2 and OmpK36 mutations.
    Int J Antimicrob Agents. 2025;65:107425.
    PubMed     Abstract available
    
    
    January 2025
57. TRIPATHI A, Jaiswal A, Kumar D, Pandit R, et al
    Whole genome sequencing revealed high occurrence of antimicrobial resistance genes in bacteria isolated from poultry manure.
    Int J Antimicrob Agents. 2025 Jan 27:107452.
    PubMed     Abstract available
    
    
    
58. EASWARAN M, Govindaraj RG, Naderi M, Brylinski M, et al
    Evaluating the antibacterial activity of engineered phage capital EF, CyrillicEcSw endolysin against multidrug-resistant Escherichia coli strain Sw1.
    Int J Antimicrob Agents. 2025;65:107395.
    PubMed     Abstract available
    
    
    
59. XU L, Lu X, Li Y, Butaye P, et al
    Eliminating the tigecycline resistance RND efflux pump gene cluster tmexCD-toprJ in bacteria using CRISPR/Cas9.
    Int J Antimicrob Agents. 2025;65:107390.
    PubMed     Abstract available
    
    
    
60. YANG W, Xu H, Zhao Y, Chen W, et al
    Identification of bla(KPC-90) in Klebsiella pneumoniae associated with ceftazidime-avibactam resistance and the translocation & truncation of resistant genes mediated by IS26.
    Int J Antimicrob Agents. 2025;65:107388.
    PubMed     Abstract available
    
    
    
61. MATAMOROS BR, Serna C, Wedel E, Montero N, et al
    NpmC - a novel A1408 16S rRNA methyltransferase in the gut of humans and animals.
    Int J Antimicrob Agents. 2025;65:107382.
    PubMed     Abstract available
    
    
    December 2024
62. ZHANG J, Du L, Shi Q, Li X, et al
    Aerosolized plus intravenous polymyxin B in comparison to intravenous polymyxin B alone for the management of HAP caused by carbapenem-resistant gram-negative bacteria: a prospective multicenter cohort study.
    Int J Antimicrob Agents. 2024 Dec 30:107427.
    PubMed     Abstract available
    
    
    
63. WAN X, Miao R, Zhang N, Huang W, et al
    Global burden of antimicrobial resistance in lower respiratory infections in 2021: a systematic analysis.
    Int J Antimicrob Agents. 2024 Dec 27:107431.
    PubMed     Abstract available
    
    
    
64. OKUMU NO, Muloi DM, Moodley A, Ochieng L, et al
    Epidemiology of antimicrobial resistant diarrheagenic Escherichia coli pathotypes from children, livestock and food in Dagoretti South, Nairobi Kenya.
    Int J Antimicrob Agents. 2024 Dec 24:107419.
    PubMed     Abstract available
    
    
    
65. PLANKAOVA A, Brajerova M, Capek V, Novotna GB, et al
    Corrigendum to "Clostridioides difficile infections were predominantly driven by fluoroquinolone-resistant Clostridioides difficile ribotypes 176 and 001 in Slovakia in 2018-2019" [International Journal of Antimicrobial Agents, 62 (2023) 1-9/106824].
    Int J Antimicrob Agents. 2024 Dec 24:107408.
    PubMed    
    
    
    
66. LIU C, Leng B, Xie M, Jiang S, et al
    Comparing ceftazidime/avibactam and polymyxin B for treating carbapenem-resistant organisms infections: a propensity score-matched retrospective cohort study.
    Int J Antimicrob Agents. 2024 Dec 20:107418.
    PubMed     Abstract available
    
    
    
67. SHI L, Yuan H, Xu J, Long J, et al
    The longitudinal trend and driving factors of antimicrobial resistance among Streptococcus pneumoniae worldwide.
    Int J Antimicrob Agents. 2024 Dec 20:107415.
    PubMed    
    
    
    
68. PENG L, Song J, Sun H, Zhang X, et al
    Molecular investigation of an epidemic dissemination of vancomycin-resistant Enterococcus faecium sequence type 80 in Guangdong Province, China.
    Int J Antimicrob Agents. 2024 Dec 19:107412.
    PubMed     Abstract available
    
    
    
69. CHUA NGS, Goh KK, Lim TP, Tang SS, et al
    Individualized Antimicrobial Therapy using Antibiotic Combination Testing and Therapeutic Drug Monitoring to Treat Carbapenem-Resistant Acinetobacter baumannii Infection.
    Int J Antimicrob Agents. 2024 Dec 19:107410.
    PubMed     Abstract available
    
    
    
70. NKENE I, Alapati S, Ribeiro A, Okoliegbe I, et al
    Genomic and growth fitness study of extended-spectrum beta-lactamase-producing Escherichia coli from bloodstream infections after introduction of a national 4C antimicrobial stewardship policy in Scotland.
    Int J Antimicrob Agents. 2024;64:107380.
    PubMed     Abstract available
    
    
    
71. YANG YS, Lee YL, Liu YM, Kuo CF, et al
    Acquired bla(CfxA-3) carried by a conjugative transposon or duplicated intrinsic bla(CME-3) mediates cefiderocol resistance in Elizabethkingia anophelis clinical isolates.
    Int J Antimicrob Agents. 2024;64:107378.
    PubMed     Abstract available
    
    
    
72. JEAN SS, Ko WC, Liu IM, Hsieh PC, et al
    Geographic differences in susceptibility profiles of potential non-class B carbapenemase-producing Enterobacterales isolates against ceftazidime-avibactam, meropenem-vaborbactam, colistin, amikacin, gentamicin, and tigecycline: Data from the Antimicro
    Int J Antimicrob Agents. 2024;64:107363.
    PubMed     Abstract available
    
    
    
73. CHEN PK, Liu CY, Kuo HY, Lee YT, et al
    Emergence of extensively-drug-resistant hypervirulent Acinetobacter baumannii isolated from patients with bacteraemia: bacterial phenotype and virulence analysis.
    Int J Antimicrob Agents. 2024;64:107358.
    PubMed     Abstract available
    
    
    November 2024
74. YANG MJ, Li MJ, Huang LD, Zhang XW, et al
    Response regulator protein CiaR regulates the transcription of ccn-microRNAs and beta-lactam antibiotic resistance conversion of Streptococcus pneumoniae.
    Int J Antimicrob Agents. 2024 Nov 18:107387.
    PubMed     Abstract available
    
    
    
75. DARWICHE FI, Hussein HM, Harb SB, Nahhal S, et al
    Investigating an outbreak of extensively drug-resistant Acinetobacter baumannii in a tertiary healthcare centre in lebanon using next-generation sequencing.
    Int J Antimicrob Agents. 2024;64:107353.
    PubMed     Abstract available
    
    
    
76. NGUYEN HK, Duke MM, Grayton QE, Broberg CA, et al
    Impact of nitric oxide donors on capsule, biofilm and resistance profiles of Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024;64:107339.
    PubMed     Abstract available
    
    
    
77. GENG X, Li Y, Hao R, Xu C, et al
    Isobavachalcone enhances sensitivity of colistin-resistant Klebsiella pneumoniae: In vitro and in vivo proof-of-concept studies.
    Int J Antimicrob Agents. 2024;64:107338.
    PubMed     Abstract available
    
    
    
78. ZHANG F, Li Z, Liu X, Li Z, et al
    In-host intra- and inter-species transfer of bla(KPC-2) and bla(NDM-1) in Serratia marcescens and its local and global epidemiology.
    Int J Antimicrob Agents. 2024;64:107327.
    PubMed     Abstract available
    
    
    October 2024
79. LIU W, Wang Z, Huang Y, Liu Y, et al
    Acetylshikonin reduces the spread of antibiotic resistance via plasmid conjugation.
    Int J Antimicrob Agents. 2024 Oct 29:107370.
    PubMed     Abstract available
    
    
    
80. OLIVA A, Curtolo A, Falletta A, Sacco F, et al
    Efficacy of fosfomycin-containing regimens in treating severe infections caused by KPC-producing Klebsiella pneumoniae and carbapenem-resistant Acinetobacter baumannii in critically ill patients.
    Int J Antimicrob Agents. 2024 Oct 26:107365.
    PubMed     Abstract available
    
    
    
81. ZHOU Y, Yang Y, Wu C, Zhou P, et al
    LuxS/AI-2 system facilitate the dissemination of antibiotic-resistant plasmids in Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024 Oct 23:107361.
    PubMed     Abstract available
    
    
    
82. CHEN Y, Li W, Liu X, Chen Y, et al
    Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Klebsiella pneumoniae with Ceftazidime-Avibactam-Based Regimens: a case report.
    Int J Antimicrob Agents. 2024 Oct 8:107356.
    PubMed     Abstract available
    
    
    
83. LIU H, Zhang Y, Zhong Z, Gong Y, et al
    Immunomodulator AS101 restores colistin susceptibility of clinical colistin-resistant Escherichia coli and Klebsiella pneumoniae in vitro and in vivo.
    Int J Antimicrob Agents. 2024;64:107285.
    PubMed     Abstract available
    
    
    
84. DING P, Li H, Nan Y, Liu C, et al
    Outcome of intravenous and inhaled polymyxin B treatment in patients with multidrug-resistant gram-negative bacterial pneumonia.
    Int J Antimicrob Agents. 2024;64:107293.
    PubMed     Abstract available
    
    
    
85. WAN TW, Huang YT, Lai JH, Chao QT, et al
    The emergence of transposon-driven multidrug resistance in invasive nontypeable Haemophilus influenzae over the last decade.
    Int J Antimicrob Agents. 2024;64:107319.
    PubMed     Abstract available
    
    
    
86. MAJDI C, Duvauchelle V, Seghir M, Benimelis D, et al
    Investigation of PhoP response regulator inhibition to overcome resistance in Gram-negative clinical bacteria.
    Int J Antimicrob Agents. 2024;64:107298.
    PubMed    
    
    
    September 2024
87. XU C, Zeng F, Xu Q, Yang Y, et al
    Effectiveness of combination therapy with intrathecal or intraventricular administration of polymyxin B for hospital-acquired central nervous system infections caused by carbapenem-resistant Acinetobacter baumannii: a retrospective study.
    Int J Antimicrob Agents. 2024 Sep 21:107334.
    PubMed     Abstract available
    
    
    
88. WU Y, Chen J, Zhang G, Li J, et al
    In vitro activities of the essential antimicrobial agents including aztreonam/avibactam, eravacycline, colistin, and other comparators against carbapenem-resistant bacteria with different carbapenemase genes: a multicenter study in China, 2021.
    Int J Antimicrob Agents. 2024 Sep 18:107341.
    PubMed     Abstract available
    
    
    
89. ZHANG M, Yang S, Liu Y, Zou Z, et al
    Anti-cancer agent 5-fluorouracil reverses meropenem resistance in carbapenem-resistant Gram-negative pathogens.
    Int J Antimicrob Agents. 2024 Sep 16:107337.
    PubMed     Abstract available
    
    
    
90. ZENG S, Kong Q, Wu X, Duan M, et al
    Antibiotic Resistance of Helicobacter pylori in Mainland China: A Focus on Geographic Differences through Systematic Review and Meta-analysis.
    Int J Antimicrob Agents. 2024 Sep 6:107325.
    PubMed     Abstract available
    
    
    
91. WEI Y, Luo H, Chen X, Yan Q, et al
    Epidemiology of subsequent Carbapenem-Resistant Enterobacterales (CRE) infection among rectal carriers: a meta-analysis of incidence, risk factors and their association with geographic region and age.
    Int J Antimicrob Agents. 2024 Sep 6:107335.
    PubMed     Abstract available
    
    
    
92. WANG WY, Chiu CF, Tsao SM, Lee YL, et al
    Accurate prediction of antimicrobial resistance and genetic marker of Staphylococcus aureus clinical isolates using MALDI-TOF MS and machine learning - Across DRIAMS and Taiwan database.
    Int J Antimicrob Agents. 2024 Sep 5:107329.
    PubMed     Abstract available
    
    
    
93. BULMAN ZP, Cao L, Curry BN, Biagi M, et al
    Ceftazidime/avibactam alone or in combination with an aminoglycoside for treatment of carbapenem-resistant Enterobacterales infections: a retrospective cohort study.
    Int J Antimicrob Agents. 2024 Sep 4:107321.
    PubMed     Abstract available
    
    
    
94. PADASAS-ADALLA CS, Ortega-Kindica RCMH, Lomeli-Ortega CO, Tabugo SRM, et al
    A metagenomics-based approach to decipher the resistome and mobilome of two seahorse species, Hippocampus barbouri and Hippocampus comes.
    Int J Antimicrob Agents. 2024;64:107296.
    PubMed     Abstract available
    
    
    
95. LIU S, Yuan D, Zhou Y, Wang B, et al
    Beware of resistance to 2nd-generation integrase inhibitors: A systematic meta-analysis of HIV-1 integrase inhibitors resistance and drug resistance mutations.
    Int J Antimicrob Agents. 2024;64:107294.
    PubMed     Abstract available
    
    
    
96. ZHANG Z, Ren R, Peng C, Ji Y, et al
    Genomic characterisation of a multidrug-resistant Klebsiella pneumoniae co-harbouring bla(NDM-1), bla(KPC-2), and tet(A) isolated from the bloodstream infections of patients.
    Int J Antimicrob Agents. 2024;64:107290.
    PubMed     Abstract available
    
    
    
97. ZHANG P, Hu J, Wu W, Shi W, et al
    Evolutionary adaptation of KPC-2-producing Pseudomonas aeruginosa high-risk sequence type 463 in a lung transplant patient.
    Int J Antimicrob Agents. 2024;64:107279.
    PubMed     Abstract available
    
    
    
98. EUZEN V, Xhaard A, Berreira-Ibraim S, Deville L, et al
    Zanamivir and baloxavir combination to cure persistent influenza and coronavirus infections after hematopoietic stem cell transplant.
    Int J Antimicrob Agents. 2024;64:107281.
    PubMed     Abstract available
    
    
    
99. LI P, Xu Q, Ding L, Zhang X, et al
    Q48K mutation in the type IB nitroreductase NrmA is responsible for nitrofurantoin resistance in Enterococcus faecium.
    Int J Antimicrob Agents. 2024;64:107277.
    PubMed     Abstract available
    
    
    
100. JAMIN C, Notermans DW, Beuken E, Maat I, et al
     KPC-85, a carbapenemase-producing and ceftazidime-avibactam-resistant KPC-3 variant found in Klebsiella pneumoniae ST512 in the Netherlands.
     Int J Antimicrob Agents. 2024;64:107271.
     PubMed    
     
     
     
101. HAN X, Yao J, He J, Liu H, et al
     Clinical and laboratory insights into the threat of hypervirulent Klebsiella pneumoniae.
     Int J Antimicrob Agents. 2024;64:107275.
     PubMed     Abstract available
     
     
     
102. YU Y, Li X, Wu Y, Lou N, et al
     Global prevalence of fosfomycin resistance genes fosA and fosB in multidrug-resistant bacteria.
     Int J Antimicrob Agents. 2024;64:107272.
     PubMed    
     
     
     
103. KURKCU MF, Yapalak ZL, Var A, Atilan K, et al
     Investigation of Mycobacterium tuberculosis complex isolates isolated from various clinical samples and their antimycobacterial resistance status: A ten-year retrospective study.
     Int J Antimicrob Agents. 2024;64:107269.
     PubMed    
     
     
     
104. TANG C, Shen S, Yang W, Shi Q, et al
     Complex evolutionary trajectories in vivo of two novel KPC variants conferring ceftazidime-avibactam resistance.
     Int J Antimicrob Agents. 2024;64:107265.
     PubMed     Abstract available
     
     
     
105. RODRIGUEZ-RUIZ JP, Lin Q, Van Heirstraeten L, Lammens C, et al
     Long-term effects of ciprofloxacin treatment on the gastrointestinal and oropharyngeal microbiome are more pronounced after longer antibiotic courses.
     Int J Antimicrob Agents. 2024;64:107259.
     PubMed     Abstract available
     
     
     
106. TELLAPRAGADA C, Razavi M, Peris PS, Jonsson P, et al
     Resistance to aztreonam-avibactam among clinical isolates of Escherichia coli is primarily mediated by altered penicillin-binding protein 3 and impermeability.
     Int J Antimicrob Agents. 2024;64:107256.
     PubMed     Abstract available
     
     
     August 2024
107. RAGHAVAN S, Kim KS
     Host immunomodulation strategies to combat pandemic-associated antimicrobial-resistant secondary bacterial infections.
     Int J Antimicrob Agents. 2024 Aug 19:107308.
     PubMed     Abstract available
     
     
     
108. DE MEDEIROS RC, Barros Dos Santos KT, Costa-Lourenco APR, Skaf LB, et al
     Neisseria gonorrhoeae ST-1901 in Rio de Janeiro from 2006 to 2022: phylogeny and antimicrobial resistance evolution of a well-succeeded pathogen.
     Int J Antimicrob Agents. 2024 Aug 12:107299.
     PubMed     Abstract available
     
     
     
109. CHOU SH, Chuang C, Juan CH, Ho YC, et al
     Mechanisms and fitness of ceftazidime/avibactam-resistant Klebsiella pneumoniae clinical strains in Taiwan.
     Int J Antimicrob Agents. 2024;64:107244.
     PubMed     Abstract available
     
     
     
110. GARCIA-FERNANDEZ S, Rodriguez-Grande J, Siller-Ruiz M, Fraile-Valcarcel N, et al
     Within-host transition to GES-55 during a GES-6-producing Serratia marcescens outbreak: Emergence of ceftazidime-avibactam resistance and increased susceptibility to carbapenems.
     Int J Antimicrob Agents. 2024;64:107257.
     PubMed     Abstract available
     
     
     
111. WANG M, Hao M, Cui X, Liu M, et al
     Tracking emergence and outbreak of Klebsiella pneumoniae co-producing NDM-1 and KPC-2 after sulfamethoxazole-trimethoprim treatment: Insights from genetic analysis.
     Int J Antimicrob Agents. 2024;64:107237.
     PubMed     Abstract available
     
     
     
112. LIU S, Zhou H, Kong J, Chen H, et al
     Verapamil increases susceptibility of colistin-resistant Acinetobacter baumannii to colistin.
     Int J Antimicrob Agents. 2024;64:107233.
     PubMed     Abstract available
     
     
     
113. TANG C, Shen S, Yang W, Shi Q, et al
     Dynamic evolution of ceftazidime-avibactam resistance from a single patient through the IncX3_NDM-5 plasmid transfer and bla(KPC) mutation.
     Int J Antimicrob Agents. 2024;64:107228.
     PubMed     Abstract available
     
     
     
114. LIAO W, Wang X, Wang Y, Ma P, et al
     Noncanonical mutations in ribosome nascent peptide exit tunnel confer clarithromycin resistance in Mycobacterium abscessus complex.
     Int J Antimicrob Agents. 2024;64:107223.
     PubMed     Abstract available
     
     
     
115. WANG WX, Wu JZ, Zhang BL, Yu JY, et al
     Phage therapy combats pan drug-resistant Acinetobacter baumannii infection safely and efficiently.
     Int J Antimicrob Agents. 2024;64:107220.
     PubMed     Abstract available
     
     
     
116. WU M, Dong Y, Zeng L, Lin Y, et al
     CRF08_BC subtype is more prone to ART failure and new-generation NNRTI-resistance under long-term first-line ART.
     Int J Antimicrob Agents. 2024;64:107215.
     PubMed     Abstract available
     
     
     
117. LAI YC, Lin LW, Lee YL
     Emergence of ceftazidime-avibactam resistance through in-vivo bla(KPC-2) to bla(KPC-33) conversion during treatment of ST11 Klebsiella pneumoniae associated infections.
     Int J Antimicrob Agents. 2024;64:107213.
     PubMed    
     
     
     
118. YANG W, Chen J, Yang F, Ji P, et al
     Identification of a novel Providencia species showing multi-drug-resistant in three patients with hospital-acquired infection.
     Int J Antimicrob Agents. 2024;64:107211.
     PubMed     Abstract available
     
     
     
119. KIEFFER N, Guzman-Puche J
     The importance of genomic context in interpreting fosfomycin resistance in Klebsiella pneumoniae.
     Int J Antimicrob Agents. 2024;64:107210.
     PubMed    
     
     
     
120. GUITART-MATAS J, Sanchez-Osuna M, Saez JL, de Frutos C, et al
     Deciphering resistance mechanisms to tigecycline and colistin in Salmonella enterica isolates from animal production.
     Int J Antimicrob Agents. 2024;64:107208.
     PubMed    
     
     
     
121. HARA GL, Antik A, Aguirre S, Giuliano C, et al
     The effect of the COVID-19 pandemic on the incidence and resistance of Gram-negative bacilli and antimicrobial consumption in the intensive care units of a referral hospital in Buenos Aires.
     Int J Antimicrob Agents. 2024;64:107203.
     PubMed     Abstract available
     
     
     
122. ZHUANG Y, Li X, Wu Y, Jia H, et al
     Colistin resistance landscape: insights into the global spread of mcr-carrying Gram-negative bacteria.
     Int J Antimicrob Agents. 2024;64:107207.
     PubMed    
     
     
     
123. RARO OHF, Bouvier M, Kerbol A, Poirel L, et al
     MultiRapid ATB NP test for detecting concomitant susceptibility and resistance of last-resort novel antibiotics available to treat multidrug-resistant Enterobacterales infections.
     Int J Antimicrob Agents. 2024;64:107206.
     PubMed     Abstract available
     
     
     July 2024
124. YADAV A, Shinde PB, Mohan H, Dhar MS, et al
     Gut colonization with antibiotic resistance Escherichia coli pathobionts leads to disease severity in ulcerative colitis.
     Int J Antimicrob Agents. 2024 Jul 29:107289.
     PubMed     Abstract available
     
     
     
125. TANG Y, Chen X, Liu C, Xue T, et al
     Policy Text Analysis of Antimicrobial Resistance Governance in China: A Focus on National-Level Policies.
     Int J Antimicrob Agents. 2024 Jul 29:107286.
     PubMed     Abstract available
     
     
     
126. YANG X, Wang T, Zhang B, Zhang W, et al
     Clinical Outcome Assessment of Colistin Sulfate in Children with Carbapenem-Resistant Organism Infections: First Data from China.
     Int J Antimicrob Agents. 2024 Jul 11:107273.
     PubMed     Abstract available
     
     
     
127. TANG Y, Yang C, Liu C, Xu Y, et al
     Development of an effective meropenem/KPC-2 inhibitor combination to combat infections caused by carbapenem-resistant K. pneumoniae.
     Int J Antimicrob Agents. 2024 Jul 5:107268.
     PubMed     Abstract available
     
     
     
128. RANDO E, Novy E, Sangiorgi F, De Pascale G, et al
     A systematic review of the pharmacokinetics and pharmacodynamics of novel beta-lactams and beta-lactam with beta-lactamase inhibitor combinations for the treatment of pneumonia caused by carbapenem-resistant Gram-negative bacteria.
     Int J Antimicrob Agents. 2024 Jul 4:107266.
     PubMed     Abstract available
     
     
     
129. CLEMENTE T, Diotallevi S, Lolatto R, Gagliardini R, et al
     Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO Registry.
     Int J Antimicrob Agents. 2024;64:107195.
     PubMed    
     
     
     
130. MESCHIARI M, Asquier-Khati A, Tiseo G, Luque-Paz D, et al
     Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
     Int J Antimicrob Agents. 2024;64:107186.
     PubMed     Abstract available
     
     
     
131. CHIU LW, Ku YE, Chan FY, Lie WN, et al
     Machine learning algorithms to predict colistin-induced nephrotoxicity from electronic health records in patients with multidrug-resistant Gram-negative infection.
     Int J Antimicrob Agents. 2024;64:107175.
     PubMed     Abstract available
     
     
     June 2024
132. BUHL MEJ, Sunnerhagen T, Join-Lambert O, Morris T, et al
     Antimicrobial resistance surveillance of Bacteroides fragilis isolated from blood cultures, Europe, 2022 (ReSuBacfrag).
     Int J Antimicrob Agents. 2024 Jun 26:107241.
     PubMed     Abstract available
     
     
     
133. HU L, Zhang XT, Zeng X, Xiong LX, et al
     ISAba1 mediated intrinsic chromosomal oxacillinase amplification confers carbapenem resistance in Acinetobacter baumannii.
     Int J Antimicrob Agents. 2024 Jun 22:107258.
     PubMed     Abstract available
     
     
     
134. XU Y, Liu D, Han P, Wang H, et al
     Rapid inference of antibiotic resistance and susceptibility for Klebsiella pneumoniae by clinical shotgun metagenomic sequencing.
     Int J Antimicrob Agents. 2024 Jun 20:107252.
     PubMed     Abstract available
     
     
     
135. LI X, Mowlaboccus S, Jackson B, Cai C, et al
     Antimicrobial Resistance Among Clinically Significant Bacteria in Wildlife: An Overlooked One Health Concern.
     Int J Antimicrob Agents. 2024 Jun 19:107251.
     PubMed     Abstract available
     
     
     
136. JOSHI PR, Joshi SD, Periasamy H, Bakthavatchalam YD, et al
     Novel beta-lactam/beta-lactamase inhibitor combinations show limited activity against Indian carbapenem-resistant Pseudomonas aeruginosa isolates due to conundrum of diverse resistance mechanisms.
     Int J Antimicrob Agents. 2024 Jun 19:107249.
     PubMed    
     
     
     
137. WANG S, Ma S, Sun S, Wang Q, et al
     Global evolutionary dynamics of virulence genes in ST11-KL47 carbapenem-resistant Klebsiella pneumoniae.
     Int J Antimicrob Agents. 2024 Jun 19:107245.
     PubMed     Abstract available
     
     
     
138. GATTI M, Virgili G, Viale P, Pea F, et al
     Is intrathecal or intraventricular therapy with polymyxins or aminoglycosides still needed to improve the outcome of post-neurosurgical extensively/multidrug-resistant Gram-negative bacteria-related meningitis/ventriculitis in the current era of novel
     Int J Antimicrob Agents. 2024;63:107177.
     PubMed    
     
     
     
139. ZHOU J, Yan G, Tang C, Liu J, et al
     Emergence of ceftazidime-avibactam resistance in bla(KPC-33)-harbouring ST11 Klebsiella pneumoniae in a paediatric patient.
     Int J Antimicrob Agents. 2024;63:107163.
     PubMed     Abstract available
     
     
     
140. BREEN SKJ, Harper M, Lopez-Causape C, Rogers KE, et al
     Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
     Int J Antimicrob Agents. 2024;63:107161.
     PubMed     Abstract available
     
     
     
141. HONG Y, Chen Y, Zhang J, Zhang H, et al
     Identification of the novel fosfomycin resistance gene fosSC in Staphylococcus capitis.
     Int J Antimicrob Agents. 2024;63:107162.
     PubMed     Abstract available
     
     
     
142. ZHAO H, Li J, Feng S, Xu L, et al
     High-throughput mutagenesis and screening approach for the identification of drug-resistant mutations in the rifampicin resistance-determining region of mycobacteria.
     Int J Antimicrob Agents. 2024;63:107158.
     PubMed     Abstract available
     
     
     May 2024
143. CHEN Q, Zhang F, Bai J, Che Q, et al
     Bacteriophage-Resistant Carbapenem-Resistant Klebsiella pneumoniae Shows Reduced Antibiotic Resistance and Virulence.
     Int J Antimicrob Agents. 2024 May 27:107221.
     PubMed     Abstract available
     
     
     
144. LAI CC, Hsueh CC, Hsu CK, Tsai YW, et al
     Disease burden and macrolide resistance of Mycoplasma pneumoniae infection in adults in Asia-Pacific region.
     Int J Antimicrob Agents. 2024 May 14:107205.
     PubMed     Abstract available
     
     
     
145. DE OLIVEIRA HC, Santos MDM, Camillo-Andrade AC, Castelli RF, et al
     Proteomics reveals that the antifungal activity of fenbendazole against Cryptococcus neoformans requires protein kinases.
     Int J Antimicrob Agents. 2024;63:107157.
     PubMed     Abstract available
     
     
     
146. YANG W, Tang C, Shen S, Shi Q, et al
     Spread and evolution of bla(KPC)-plasmid between Serratia marcescens and Klebsiella pneumoniae.
     Int J Antimicrob Agents. 2024;63:107149.
     PubMed     Abstract available
     
     
     
147. LIM C, Coombs GW, Daley DA, Shoby P, et al
     Whole-genome sequencing identifies MprF mutations in a genetically diverse population of daptomycin non-susceptible Staphylococcus aureus in Australia.
     Int J Antimicrob Agents. 2024;63:107144.
     PubMed     Abstract available
     
     
     
148. XU H, Tan C, Li C, Li J, et al
     ESBL-Escherichia coli extracellular vesicles mediate bacterial resistance to beta-lactam and mediate horizontal transfer of bla(CTX-M-55).
     Int J Antimicrob Agents. 2024;63:107145.
     PubMed     Abstract available
     
     
     
149. MONTE DFM, de Oliveira CJB
     Silent dissemination of fosfomycin resistance genes in critical-priority Klebsiella pneumoniae.
     Int J Antimicrob Agents. 2024;63:107139.
     PubMed    
     
     
     
150. LONG H, Zhao F, Feng Y, Zong Z, et al
     Global distribution of bla(CMY-42), a gene mediating reduced susceptibility to aztreonam-avibactam and ceftazidime-avibactam, in Escherichia coli.
     Int J Antimicrob Agents. 2024;63:107141.
     PubMed    
     
     
     
151. MESCHIARI M, Faltoni M, Kaleci S, Tassoni G, et al
     Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant Gram-negative organisms: A real-life experience.
     Int J Antimicrob Agents. 2024;63:107134.
     PubMed     Abstract available
     
     
     
152. MEZCORD V, Traglia GM, Pasteran F, Escalante J, et al
     Characterisation of cefiderocol-resistant spontaneous mutant variants of Klebsiella pneumoniae-producing NDM-5 with a single mutation in cirA.
     Int J Antimicrob Agents. 2024;63:107131.
     PubMed    
     
     
     
153. ATHANASSA Z, Manioudaki S, Petsa I, Koumaki V, et al
     Effectiveness and safety of minocycline combination therapy for the treatment of patients with ventilator-associated pneumonia due to extensively drug- or pandrug-resistant Acinetobacter baumannii.
     Int J Antimicrob Agents. 2024;63:107129.
     PubMed    
     
     
     
154. WANG L, Zhou X, Lu Y, Zhang X, et al
     Levofloxacin-induced MexS mutation triggers imipenem-relebactam resistance in a KPC-producing Pseudomonas aeruginosa.
     Int J Antimicrob Agents. 2024;63:107119.
     PubMed     Abstract available
     
     
     
155. HSU CK, Lai CC, Chen CC, Chen HJ, et al
     Evaluation of three brands of Mueller-Hinton media for broth microdilution method to determine the susceptibility of multidrug-resistant Gram-negative bacilli against eravacycline.
     Int J Antimicrob Agents. 2024;63:107117.
     PubMed    
     
     
     
156. AMODIO E, Pizzo S, Vella G, De Francisci V, et al
     Increase of multidrug-resistant bacteria after the COVID-19 pandemic in a major teaching Hospital in Sicily (2018-2021).
     Int J Antimicrob Agents. 2024;63:107123.
     PubMed     Abstract available
     
     
     April 2024
157. RUSSO A, Gulli SP, D'Avino A, Borrazzo C, et al
     Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a multicenter clinical experience.
     Int J Antimicrob Agents. 2024 Apr 30:107190.
     PubMed     Abstract available
     
     
     
158. ZHUANG H, Chen M, Hu D, Liu L, et al
     Role of tcaA, a potential target as a ceftobiprole resistance breaker, in MRSA beta-lactam resistance.
     Int J Antimicrob Agents. 2024 Apr 29:107185.
     PubMed     Abstract available
     
     
     
159. FRIMODT-MOLLER N, Hansen JU, Plattner M, Huseby DL, et al
     Apramycin efficacy against carbapenem- and aminoglycoside-resistant Escherichia coli and Klebsiella pneumoniae in murine blood stream infection models.
     Int J Antimicrob Agents. 2024 Apr 21:107181.
     PubMed     Abstract available
     
     
     
160. SALLEE L, Souchet L, Boutolleau D, Nguyen S, et al
     Amenamevir for Treating Acyclovir-Resistant or Refractory Herpes Simplex Virus Infection in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Two Case Reports.
     Int J Antimicrob Agents. 2024 Apr 10:107169.
     PubMed    
     
     
     
161. VO T, Pontarotti P, Rolain JM, Merhej V, et al
     Mechanisms of acquisition of vanA operon among vancomycin-resistant Staphylococcus aureus genomes: the tip of the iceberg?
     Int J Antimicrob Agents. 2024 Apr 8:107154.
     PubMed     Abstract available
     
     
     
162. GILL K, Takamichi B, Cooper A
     Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: new data from CREDIBLE-CR with an updated meta-analysis.
     Int J Antimicrob Agents. 2024 Apr 4:107167.
     PubMed    
     
     
     
163. GATTI M, Cosentino F, Giannella M, Viale P, et al
     In reply to the Letter to the Editor regarding "Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis".
     Int J Antimicrob Agents. 2024 Apr 4:107168.
     PubMed    
     
     
     
164. MONTE DFM, de Oliveira CJB
     A 22-year Brazilian colistin resistance surveillance on Escherichia coli and Salmonella spp. originating from food-producing animals.
     Int J Antimicrob Agents. 2024;63:107114.
     PubMed    
     
     
     March 2024
165. HU J, Zha L, Yu YW, Su Q, et al
     Efficacy of Ceftazidime-Avibactam in the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections: focus on Solid Organ Transplantation Recipients.
     Int J Antimicrob Agents. 2024 Mar 19:107152.
     PubMed     Abstract available
     
     
     
166. HO LC, Yu Chi C, You YS, Hsieh YW, et al
     Impact of the implementation of the Intelligent Antimicrobial System (iAMS) on clinical outcomes among patients with bacteraemia caused by methicillin-resistant Staphylococcus aureus.
     Int J Antimicrob Agents. 2024 Mar 13:107142.
     PubMed     Abstract available
     
     
     February 2024
167. KHARAT AS, Makwana N, Nasser M, Gayen S, et al
     Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010-2020 decade in India.
     Int J Antimicrob Agents. 2024 Feb 29:107125.
     PubMed     Abstract available
     
     
     
168. WANG C, Bai C, Chen K, Du Q, et al
     International guidelines for the treatment of carbapenem-resistant Gram-negative bacilli infections: a comparison and evaluation.
     Int J Antimicrob Agents. 2024 Feb 26:107120.
     PubMed     Abstract available
     
     
     
169. BOATTINI M, Bianco G, Llorente LI, Acero LA, et al
     Enterobacterales carrying chromosomal AmpC beta-lactamases in Europe (EuESCPM): epidemiology and antimicrobial resistance burden from a cohort of 27 hospitals, 2020-2022.
     Int J Antimicrob Agents. 2024 Feb 15:107115.
     PubMed     Abstract available
     
     
     
170. YANG L, Gao Y, Zhang J, Tian C, et al
     Antimicrobial peptide DvAMP combats carbapenem-resistant Acinetobacter baumannii infection.
     Int J Antimicrob Agents. 2024 Feb 5:107106.
     PubMed     Abstract available
     
     
     
171. WANG JL, Lai CC, Tsai YW, Ko WC, et al
     High ceftazidime-avibactam resistance among carbapenem-resistant Enterobacter species: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2014-2021.
     Int J Antimicrob Agents. 2024 Feb 5:107105.
     PubMed     Abstract available
     
     
     
172. SIVAY MV, Maksimenko LV, Nalimova TM, Nefedova AA, et al
     HIV drug resistance among patients experiencing antiretroviral therapy failure in Russia, 2019-2021.
     Int J Antimicrob Agents. 2024;63:107074.
     PubMed     Abstract available
     
     
     
173. CHEN H, Hu P, Liu H, Liu S, et al
     Combining with domiphen bromide restores colistin efficacy against colistin-resistant Gram-negative bacteria in vitro and in vivo.
     Int J Antimicrob Agents. 2024;63:107066.
     PubMed     Abstract available
     
     
     
174. WANG C, Zhang T, Wang Y, Wang Y, et al
     Proguanil and chlorhexidine augment the antibacterial activities of clarithromycin and rifampicin against Acinetobacter baumannii.
     Int J Antimicrob Agents. 2024;63:107065.
     PubMed     Abstract available
     
     
     January 2024
175. FENG Y, Fang Q, Luo H, Li J, et al
     Safety and efficacy of a phage cocktail on murine wound infections caused by carbapenem-resistant Klebsiella pneumoniae.
     Int J Antimicrob Agents. 2024 Jan 11:107088.
     PubMed     Abstract available
     
     
     
176. HSUEH CC, Lai CC, Tsai YW, Ko WC, et al
     Poor in vitro activity of ceftazidime/avibactam against carbapenem-resistant Escherichia coli and Klebsiella pneumoniae in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.
     Int J Antimicrob Agents. 2024 Jan 11:107087.
     PubMed    
     
     
     
177. HERSHKO Y, Rannon E, Adler A, Burstein D, et al
     WarA, a remote homolog of NpmA and KamB from Nocardia wallacei, confers broad spectrum aminoglycoside resistance in Nocardia and Mycobacteria.
     Int J Antimicrob Agents. 2024 Jan 11:107089.
     PubMed     Abstract available
     
     
     
178. MUSHTAQ S, Vickers A, Woodford N, Livermore DM, et al
     Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance.
     Int J Antimicrob Agents. 2024 Jan 2:107081.
     PubMed     Abstract available
     
     
     
179. RATOUIT P, Malet I, Soulie C, Denis J, et al
     HIV-1 resistance mutations to integrase inhibitors impair both integration and reverse transcription steps.
     Int J Antimicrob Agents. 2024;63:107026.
     PubMed    
     
     
     
180. PARK S, Choi J, Shin D, Kwon KT, et al
     Conversion to colistin susceptibility by tigecycline exposure in colistin-resistant Klebsiella pneumoniae and its implications to combination therapy.
     Int J Antimicrob Agents. 2024;63:107017.
     PubMed     Abstract available
     
     
     
181. KIM SJ, Shin JH, Kim H, Ko KS, et al
     Roles of crrAB two-component regulatory system in Klebsiella pneumoniae: growth yield, survival in initial colistin treatment stage, and virulence.
     Int J Antimicrob Agents. 2024;63:107011.
     PubMed     Abstract available
     
     
     December 2023
182. DU Y, Wang Y, Geng J, Long J, et al
     Molecular Mechanism of Hfq-dependent sRNA1039 and sRNA1600 Regulating Antibiotic Resistance and Virulence in Shigella sonnei.
     Int J Antimicrob Agents. 2023 Dec 21:107070.
     PubMed     Abstract available
     
     
     
183. YU MC, Huang CK, Hung CS, Wang CH, et al
     Emerging insight of whole genome sequencing coupled with protein structure prediction into the pyrazinamide-resistance signature of Mycobacterium tuberculosis.
     Int J Antimicrob Agents. 2023 Dec 9:107053.
     PubMed     Abstract available
     
     
     
184. KIAROSTAMI K, Fernandez-Barat L, Battaglini D, Motos A, et al
     The efficacy of telavancin in comparison with linezolid on endotracheal tube biofilm in pigs with methicillin-resistant Staphylococcus aureus pneumonia.
     Int J Antimicrob Agents. 2023 Dec 8:107052.
     PubMed     Abstract available
     
     
     
185. JEON E, Kim MK, Park Y
     Efficacy of the bee-venom antimicrobial peptide Osmin against sensitive and carbapenem-resistant Klebsiella pneumoniae strains.
     Int J Antimicrob Agents. 2023 Dec 8:107054.
     PubMed     Abstract available
     
     
     
186. GATTI M, Cosentino F, Giannella M, Viale P, et al
     Clinical efficacy of cefiderocol-based regimens in patients affected by carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis.
     Int J Antimicrob Agents. 2023 Dec 5:107047.
     PubMed     Abstract available
     
     
     
187. HU T, Wang S, Bing J, Zheng Q, et al
     Hotspot mutations and genomic expansion of ERG11 are major mechanisms of azole resistance in environmental and human commensal isolates of Candida tropicalis.
     Int J Antimicrob Agents. 2023;62:107010.
     PubMed     Abstract available
     
     
     November 2023
188. WANG SH, Yang KY, Sheu CC, Lin YC, et al
     Efficacy of combination therapy with standard-dose carbapenem for treating nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii in intensive care units: a multicenter retrospective propensity score-matched study.
     Int J Antimicrob Agents. 2023 Nov 29:107044.
     PubMed     Abstract available
     
     
     
189. KUANG SF, Xiang J, Chen YT, Peng XX, et al
     Exogenous pyruvate promotes gentamicin uptake to kill antibiotic-resistant Vibrio alginolyticus.
     Int J Antimicrob Agents. 2023 Nov 17:107036.
     PubMed     Abstract available
     
     
     
190. MUKHOPADHYAY S, Zhang P, To KKW, Liu Y, et al
     Sequential treatment effects on phage-antibiotic synergistic application against multi-drug-resistant Acinetobacter baumannii.
     Int J Antimicrob Agents. 2023;62:106951.
     PubMed     Abstract available
     
     
     October 2023
191. XU C, Zeng F, Huang Y, Xu Q, et al
     Clinical Efficacy of Ceftazidime/avibactam Combination Therapy for Severe Hospital-acquired Pulmonary Infections Caused by Carbapenem-Resistant and Difficult-to-Treat Pseudomonas aeruginosa.
     Int J Antimicrob Agents. 2023 Oct 25:107021.
     PubMed     Abstract available
     
     
     
192. CANTON R, Gottlieb T, Coombs GW, Woo PCY, et al
     Antimicrobial surveillance: a 20-year history of the SMART approach to addressing global antimicrobial resistance into the future.
     Int J Antimicrob Agents. 2023 Oct 20:107014.
     PubMed     Abstract available
     
     
     
193. YU J, Lin HH, Tseng KH, Lin YT, et al
     Prediction of methicillin-resistant Staphylococcus aureus and carbapenem-resistant Klebsiella pneumoniae from flagged blood cultures by combining rapid Sepsityper MALDI-TOF mass spectra with machine learning.
     Int J Antimicrob Agents. 2023 Oct 4:106994.
     PubMed     Abstract available
     
     
     
194. TAO H, Liu L, Chen X, Peng L, et al
     Coexistence of Klebsiella pneumoniae and Acinetobacter baumannii contributes to antibiotic resistance.
     Int J Antimicrob Agents. 2023 Oct 2:106993.
     PubMed    
     
     
     
195. WANG Q, Peng K, Liu Z, Li Y, et al
     Genomic insights into linezolid-resistant Enterococci revealed its evolutionary diversity and poxtA copy number heterogeneity.
     Int J Antimicrob Agents. 2023;62:106929.
     PubMed     Abstract available
     
     
     
196. GUILLAMET MCV, Damulira C, Atkinson A, Fraser VJ, et al
     Addition of aminoglycosides reduces recurrence of infections with multidrug-resistant Gram-negative bacilli in patients with sepsis and septic shock.
     Int J Antimicrob Agents. 2023;62:106913.
     PubMed     Abstract available
     
     
     September 2023
197. CAI T, Novelli A, Tascini C, Stefani S, et al
     Rediscovering the value of fosfomycin trometamol in the era of antimicrobial resistance: a systematic review and expert opinion.
     Int J Antimicrob Agents. 2023 Sep 23:106983.
     PubMed     Abstract available
     
     
     
198. LIU JY, Jia JJ, Liu M, Duan H, et al
     A novel indolylbenzoquinone compound HL-J6 suppresses biofilm formation and alpha-toxin secretion in methicillin-resistant Staphylococcus aureus.
     Int J Antimicrob Agents. 2023 Sep 21:106972.
     PubMed     Abstract available
     
     
     
199. CAI T, Verze P, Arcaniolo D, Pandolfo SD, et al
     ANTIBIOTIC RESISTANCE PATTERNS AMONG UROPATHOGENS IN FEMALE OUTPATIENTS AFFECTED BY UNCOMPLICATED CYSTITIS: FOCUS ON FOSFOMYCIN TROMETAMOL.
     Int J Antimicrob Agents. 2023 Sep 20:106974.
     PubMed     Abstract available
     
     
     
200. WU JW, Quyen TLT, Hsieh YC, Chen YY, et al
     Investigation of carbapenem-resistant Klebsiella pneumoniae in Taiwan revealed strains co-harboring bla(NDM) and bla(OXA-48-like) and a novel plasmid co-carrying bla(NDM-1) and bla(OXA-181).
     Int J Antimicrob Agents. 2023 Sep 4:106964.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Drug Resistance is free of charge.